

CLAIMS

1. The use of a Gas6 compound for the manufacture of a medicament for the treatment or prevention of anemia.

5

2. The use according to claim 1 wherein the Gas6 compound is Gas6 protein or an analogue, mutant, variant or derivative thereof, or a physiologically tolerated salt of said Gas6 derivative.

- 10 3. The use of biologically active substances inducing a Gas6 expression or release for the manufacture of a medicament for the prevention or treatment of anemia.

15

4. The use according to claim 3, wherein the biologically active substance is a vector comprising the Gas6 gene.
5. The use according to any of the claims 1 to 4, wherein said treatment or prevention is the treatment or prevention of a patient susceptible to the adverse side-effects of Epo.

20

6. The use according to claim 5, wherein said patient susceptible to the adverse side-effects of Epo is a patient suffering from hypertension.
7. The use of a Gas6 compound for the manufacture of a medicament for the treatment or prevention of anemia in a patient irresponsive to Epo.

- 25 8. The use according to claim 7 wherein the Gas6 compound is Gas6 or an analogue, mutant, variant or derivative thereof, or a physiologically tolerated salt of said Gas6 derivative.

30

9. The use of a Gas6 compound in combination with erythropoietin or an analogue, mutant, variant or derivative thereof, or a physiologically tolerated

salt of said EPO derivative for the manufacture of an antianemic drug or an antianemic composition.

10. The use according to claim 9, wherein the Gas6 compound is Gas6 or an 5 analogue, mutant or derivative thereof, or a physiologically tolerated salt of said Gas6 derivative,

11. The use according to claim 10, wherein said antianemic drug is a drug for the treatment or prevention of anemia in a patient for which treatment with 10 Epo is contra-indicated.

12. The use of claim 10, wherein said antianemic drug is a drug for the treatment or prevention of anemia in a patient irresponsive to Epo or an 15 analogue, mutant, variant or derivative thereof, or a physiologically tolerated salt of said EPO derivative.

13. A method for the treatment, curing or prevention of anemia in a patient which is irresponsive to Epo, which method comprises: administering thereto 20 an optimized combination of a Gas6 compound and erythropoietin or an analogue, mutant, variant or derivative thereof, or a physiologically tolerated salt of said EPO derivative, either simultaneously or sequentially, said optimized concentration ensuring a target or normalized hemoglobin level.

14. The method according to claim 13 wherein the Gas6 compound is Gas6 or 25 an analogue, mutant or derivative thereof, or a physiologically tolerated salt of said Gas6 derivative.

15. A method for the treatment, curing or prevention of anemia in a patient for which treatment with Epo is contra-indicated, which method comprises: 30 administering to said patient an optimized combination of a Gas6 compound, and erythropoietin or an analogue, mutant, variant or derivative thereof, or a physiologically tolerated salt of said EPO derivative, either simultaneously or

sequentially, said optimized concentration ensuring a target or normalized hemoglobin level.

16. The method of claim 15, wherein the Gas6 compound is Gas6 or an analogue, mutant or derivative thereof, or a physiologically tolerated salt of said Gas6 derivative.
5
17. An antianemic pharmaceutical composition comprising a Gas6 compound, or an optimized formulation of such a Gas6 compound with erythropoietin or an analogue, mutant, variant or derivative thereof, or a physiologically tolerated salt of said EPO derivative.
10
18. The composition according to claim 17, wherein the Gas6 compound is Gas or an analogue, mutant or derivative thereof, or a physiological tolerated salt of said Gas6 derivative.
15
19. A method of selection of a formulation of a pharmaceutical ratio of a gas6 compound to Epo or an analogue, mutant, variant or derivative thereof, or a physiologically tolerated salt of said EPO derivative, said method comprising:
20
 - a) determining the minimal dose of Epo or an analogue, mutant, variant or derivative thereof, or a physiologically tolerated salt of said EPO derivative which does not induce adverse side-effects in a patient; and
 - b) administering in addition to a) incremental doses of a Gas6 compound so as to determine which combined Epo/Gas6 dosage ensures maintenance of target hemoglobin levels in said patient
25
 - c) selecting the ratio in accordance with the determination of step b).
20. The method according to claim 19, further comprising preparing a pharmaceutical composition comprising the selected ratio of the EPO or the analogue, mutant, variant or derivative thereof, or the physiologically tolerated salt of said EPO derivative to the Gas6 compound.
30